LiDCO Group Plc Capital Markets Day
April 24 2018 - 1:01AM
RNS Non-Regulatory
TIDMLID
LiDCO Group Plc
24 April 2018
LiDCO Group Plc
("LiDCO" or the "Company")
Capital Markets Day
LiDCO (AIM: LID), the hemodynamic monitoring company, announces
it will be holding a Capital Markets Day for investors on Wednesday
16 May 2018.
A presentation with be given by CEO Matt Sassone, who will
provide an overview of the Company and where it is currently
positioned. The afternoon will also feature presentations by:
-- Shane Doorish, Head of North America
Shane joined LiDCO in January 2017 bringing with him 19 years of
experience in the healthcare sector having originally trained as a
critical care nurse. This includes 12 years with Edwards
Lifesciences, a major global provider of hemodynamic monitoring,
where Shane held a number of sales and marketing positions.
-- Eric Mills, Head of Technology
Eric has been at LiDCO for over 14 years having overseen the
transformation of the technology to its current non-invasive form.
He has a wealth of expertise in the hemodynamic monitoring
market.
-- Dr Max Jonas, Clinical Adviser
Dr Jonas is a Consultant Intensivist, Senior Lecturer and Tutor
in critical care working at Southampton University and Hospitals.
He is currently a senior consultant on the 28 bed general intensive
care unit and has specific interests in hemodynamics and health
technology assessment. He is an elected member of the Council of
the Intensive Care Society and has completed a six year term of the
technology assessment section of the European Society of Intensive
Care Medicine.
The event will be held at LiDCO's HQ, 16 Orsman Road, London, N1
5QJ at 4pm. This will be followed by light refreshments and an
opportunity to talk to senior management further.
The presentation will be available on the Company website
shortly after the event, and no new material or trading information
will be provided.
To register, please email lidco@walbrookpr.com or telephone
Walbrook PR on the number below.
For further information, please contact:
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, originally developed at St Thomas' Hospital in London,
has been shown to significantly reduce morbidity and complications,
length of stay and overall costs associated with major surgery.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring. Version 2
of this software is only available on a new slim widescreen monitor
and includes the optional high usage program software in selected
markets.
LiDCOplus: a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness.
LiDCOrapid: a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview: an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS(TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFIRSAIVFIT
(END) Dow Jones Newswires
April 24, 2018 02:01 ET (06:01 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024